Star Combo Pharma Ltd. (S66) AI Stock Analysis

• Market Cap: AU$26.33M
• Dividend Yield: 1.9%
• Average Volume (3M): 8.24K
• Price to Earnings (P/E): 5.0
• Beta (1Y): -0.08
• Revenue Growth: 6.89%
• EPS Growth: 607.27%
• Country: AU
• Employees: N/A
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): 0.04
• Shares Outstanding: 135,002,980
• 10 Day Avg. Volume: 10,429
• 30 Day Avg. Volume: 8,240
• PEG Ratio: 0.01
• Price to Book (P/B): 0.63
• Price to Sales (P/S): 0.86
• P/FCF Ratio: 2.08
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 66 Neutral
• Price Target: AU$0.00 ▼(-100.00% Downside)

Star Combo Pharma Ltd. has a solid financial foundation with strong profitability and cash flow generation, contributing significantly to its overall score. The stock appears undervalued based on its low P/E ratio and offers a decent dividend yield. However, technical indicators suggest short-term bearish momentum, which slightly offsets the positive financial and valuation aspects.

Star Combo Pharma Ltd. Business Overview & Revenue Model

Company Description

Star Combo Pharma Ltd. (S66) is a pharmaceutical and healthcare company based in Australia, specializing in the development and distribution of a wide range of health products, including dietary supplements, over-the-counter medications, and prescription pharmaceuticals. The company operates within the health and wellness sector, focusing on natural and innovative solutions to meet consumer needs. Star Combo Pharma aims to improve health outcomes through high-quality products that are backed by scientific research and development.

How the Company Makes Money

Star Combo Pharma generates revenue primarily through the sale of its healthcare products, which include both prescription and over-the-counter medications, as well as dietary supplements. The company leverages a multi-channel distribution strategy, selling its products through pharmacies, health food stores, and online platforms. Key revenue streams include direct sales to consumers and partnerships with healthcare professionals and retail distributors. Additionally, the company may engage in collaborations or partnerships with other firms for product development and distribution, which can also contribute to its earnings. Factors such as market demand for health products, regulatory approvals, and the effectiveness of its marketing strategies significantly influence its financial performance.

Star Combo Pharma Ltd. Financial Statement Overview

Summary

Star Combo Pharma Ltd. demonstrates a solid financial performance with improvements in profitability and cash flow generation. The company has managed to enhance its profit margins and maintain a strong balance sheet with low leverage. However, revenue growth has been a challenge, and attention should be given to improving operational efficiency to sustain long-term profitability.

Income Statement

Star Combo Pharma Ltd. has shown a mixed performance in its income statement. The company experienced a decline in revenue growth rate by 6.34% in the latest year, indicating a contraction in sales. However, the gross profit margin improved to 22.55%, reflecting better cost management. The net profit margin also increased significantly to 18.87%, driven by a substantial rise in net income. Despite these improvements, the EBIT margin remains negative, suggesting challenges in operational efficiency.

Balance Sheet

The balance sheet of Star Combo Pharma Ltd. reflects a stable financial position with a low debt-to-equity ratio of 0.10, indicating conservative leverage. The return on equity improved to 13.78%, showcasing enhanced profitability for shareholders. The equity ratio stands at a healthy level, suggesting a strong capital structure. Overall, the balance sheet indicates financial stability with a low risk of financial distress.

Cash Flow

The cash flow statement shows a robust improvement with a free cash flow growth rate of 178.51%, highlighting strong cash generation capabilities. The operating cash flow to net income ratio is 2.04, indicating efficient cash conversion from earnings. The free cash flow to net income ratio is close to 1, suggesting that the company is effectively converting its profits into cash. These metrics reflect a solid cash flow position, supporting future growth and investment opportunities.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	27.81M	27.81M	26.02M	24.70M	22.88M	26.72M
Gross Profit	6.27M	6.27M	5.44M	4.66M	5.61M	4.61M
EBITDA	6.64M	6.64M	2.79M	-2.53M	-126.71K	-6.40M
Net Income	5.25M	5.25M	747.33K	-4.00M	-696.35K	-7.88M
Balance Sheet
Total Assets	48.45M	48.45M	42.82M	42.23M	43.44M	43.32M
Cash, Cash Equivalents and Short-Term Investments	18.11M	18.11M	7.36M	9.49M	10.39M	17.32M
Total Debt	3.93M	3.93M	4.03M	4.19M	4.12M	3.30M
Total Liabilities	10.19M	10.19M	9.30M	8.97M	8.04M	7.13M
Stockholders Equity	38.08M	38.08M	33.32M	33.09M	35.41M	36.19M
Cash Flow
Free Cash Flow	11.55M	11.55M	-1.76M	-851.83K	-7.21M	-6.93M
Operating Cash Flow	11.94M	11.94M	-316.45K	1.88M	87.11K	331.53K
Investing Cash Flow	-9.72M	-9.72M	-136.79K	-3.23M	-3.24M	-7.53M
Financing Cash Flow	-795.12K	-795.12K	-370.93K	-53.44K	-169.08K	-2.08M

Star Combo Pharma Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.20
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:S66, the sentiment is Negative. The current price of 0.2 is below the 20-day moving average (MA) of 0.21, below the 50-day MA of 0.22, and above the 200-day MA of 0.17, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 37.42 is Neutral, neither overbought nor oversold. The STOCH value of 46.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:S66.

Star Combo Pharma Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
S66	66 Neutral	AU$26.33M	5.01	14.70%	1.90%	6.89%	607.27%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
LDX	46 Neutral	AU$149.56M	―	-111.23%	―	12.96%	40.81%
AGH	41 Neutral	AU$19.03M	-1.28	―	―	-47.30%	82.53%
ZNO	40 Underperform	AU$18.69M	-4.55	-77.92%	―	17.41%	67.94%
NC6	40 Underperform	AU$17.03M	-7.94	-1651.76%	―	-100.00%	2.86%
SKN	30 Underperform	AU$7.24M	―	―	―	12.92%	34.21%

Star Combo Pharma Ltd. Corporate Events

Star Combo Pharma Ltd. Releases 2025 Corporate Governance Statement

Star Combo Pharma Ltd. has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles, emphasizing transparency and accountability in its management and board practices. This announcement reinforces the company’s commitment to maintaining robust governance standards, which is crucial for its stakeholders and industry positioning.

The most recent analyst rating on (AU:S66) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on Star Combo Pharma Ltd. stock, see the AU:S66 Stock Forecast page.

Star Combo Pharma Ltd. Releases 2025 Corporate Governance Statement

Star Combo Pharma Ltd. has released its Corporate Governance Statement for 2025, outlining its commitment to solid management foundations and oversight. The company has implemented a diversity policy to promote gender equality, with specific objectives for achieving gender diversity within its workforce. As of September 2025, the company reports a 38% female representation across its staff, reflecting its ongoing efforts to enhance workplace diversity.

The most recent analyst rating on (AU:S66) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on Star Combo Pharma Ltd. stock, see the AU:S66 Stock Forecast page.

Star Combo Pharma Ltd. Announces 2025 AGM and Key Resolutions

Star Combo Pharma Ltd. has announced its 2025 Annual General Meeting (AGM) scheduled for November 25th, 2025, at its Smithfield, NSW headquarters. The meeting will address key business items including the consideration of financial statements, the adoption of the remuneration report, and the re-election of Ms. Wei Han as a director. Shareholders can participate in person, via proxy, or online, highlighting the company’s efforts to ensure inclusive shareholder engagement.

The most recent analyst rating on (AU:S66) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on Star Combo Pharma Ltd. stock, see the AU:S66 Stock Forecast page.

Star Combo Pharma Announces 2025 AGM Date

Star Combo Pharma Ltd has announced that its annual General Meeting will be held on November 25, 2025. The company has set October 19, 2025, as the deadline for director nominations. This meeting is a significant event for stakeholders as it provides an opportunity to discuss the company’s strategic direction and elect new directors, potentially impacting its future operations and market positioning.

The most recent analyst rating on (AU:S66) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on Star Combo Pharma Ltd. stock, see the AU:S66 Stock Forecast page.

Star Combo Pharma Ltd. Announces New Dividend Distribution

Star Combo Pharma Ltd. has announced a new dividend distribution of AUD 0.00370143 per share, with an ex-date of October 14, 2025, and a payment date set for October 31, 2025. This announcement reflects the company’s ongoing commitment to returning value to its shareholders, potentially enhancing investor confidence and solidifying its market position.

Star Combo Pharma Reports Strong Financial Growth and Positive Outlook

Star Combo Pharma Ltd reported a significant increase in profit after tax to $5.25 million for the financial year ending June 30, 2025, attributed to strong revenue growth and the settlement of an insurance claim. The company declared its second dividend, reflecting confidence in its business stability, and anticipates further production capacity expansion by the end of FY2026, indicating a positive outlook for the future.

Star Combo Pharma Ltd. Releases 2025 Preliminary Final Report

Star Combo Pharma Ltd. has released its preliminary final report for the year ending June 30, 2025, which outlines the company’s financial performance and operational highlights. This report is crucial for stakeholders as it provides insights into the company’s financial health and strategic direction, potentially impacting its market positioning and investor confidence.